Literature DB >> 19067742

Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia.

Ronald Adler1, Susanne Viehmann, Eberhard Kuhlisch, Yvonne Martiniak, Silja Röttgers, Jochen Harbott, Meinolf Suttorp.   

Abstract

BACKGROUND AND
OBJECTIVE: The characteristic chromosomal translocation t(9;22)(q34;q11) in chronic myeloid leukaemia (CML) mainly results in the two different BCR/ABL fusion transcripts b2a2 or b3a2. Both transcript variants can occur simultaneously due to alternative splicing of the b3a2 transcript. Conflicting results have been reported on the influence of the transcripts on haematological findings at diagnosis and the course of the disease in adults while data concerning these topics on childhood CML are still missing. This paper reports on a correlation of BCR/ABL transcript variants with patients' characteristics in childhood CML. DESIGN AND METHODS: Transcript types were determined in 146 paediatric patients with CML enrolled in trial CML-paed-I. Fifty-five patients (38%) expressed b2a2, 53 patients (36%) b3a2 and 38 patients (26%) both transcripts, respectively. These findings were correlated with patients' characteristics (sex, age, WBC, Hb, platelet count, hepatosplenomegaly, etc.) assessed at diagnosis.
RESULTS: While the co-expression of both transcripts was evenly distributed among genders [b2a2 + b3a2: 22 females (28%), 16 males (24%)] a highly significant difference (P = 0.007) was found concerning the expression of the b2a2 transcript [34 male (51%) vs. 21 female (27%)] and vice versa of the b3a2 transcript [17 male (25%) vs. 36 female (45%)]. High platelet counts and the combination of high platelet counts in conjunction with pronounced leukocytosis were observed more often in patients expressing the b3a2 transcript.
CONCLUSIONS: These findings demonstrate that in children like in adults specific BCR/ABL transcript types present at diagnosis are associated with distinct haematological alterations (e.g. a high platelet count with the transcript b3a2). However, the sex-dependent skewed distribution of the BCR/ABL transcript types observed so far in this paediatric cohort only deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19067742     DOI: 10.1111/j.1600-0609.2008.01170.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  9 in total

1.  Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.

Authors:  Meinolf Suttorp; Christian Thiede; Josephine T Tauer; Ursula Range; Brigitte Schlegelberger; Nils von Neuhoff
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

2.  Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.

Authors:  Nobuko Hijiya; Kirk R Schultz; Markus Metzler; Frederic Millot; Meinolf Suttorp
Journal:  Blood       Date:  2015-10-28       Impact factor: 22.113

3.  Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Andrea Davies; Katy Knight; Sarah J Watmough; Lihui Wang; Richard E Clark
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

4.  Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia.

Authors:  Ayda Bennour; Ines Ouahchi; Bechir Achour; Monia Zaier; Yosra Ben Youssef; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Med Oncol       Date:  2012-12-27       Impact factor: 3.064

5.  Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients.

Authors:  Emad-Aldin I Osman; Kamal Hamad; Imad M Fadl Elmula; Muntaser E Ibrahim
Journal:  Genet Mol Biol       Date:  2010-06-01       Impact factor: 1.771

6.  Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia - a possible influence of mdr1 gene expression.

Authors:  Gueorgui Balatzenko; Babu Rao Vundinti; Guenova Margarita
Journal:  Hematol Rep       Date:  2011-03-23

7.  Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.

Authors:  Mahmood S Khazaal; Farqad B Hamdan; Qasim S Al-Mayah
Journal:  Mol Genet Genomic Med       Date:  2019-06-17       Impact factor: 2.183

8.  Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Jianqin Shan; Elias Jabbour; Alfonso Quintas-Cardama; Srdan Verstovsek; Farhad Ravandi; William Wierda; Susan O'Brien; Jorge Cortes
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

9.  Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.

Authors:  Lida Kalmanti; Susanne Saussele; Michael Lauseker; Ulrike Proetel; Martin C Müller; Benjamin Hanfstein; Annette Schreiber; Alice Fabarius; Markus Pfirrmann; Susanne Schnittger; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Stefan W Krause; Dominik Heim; Christoph Nerl; Dieter K Hossfeld; Hans-Jochem Kolb; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann
Journal:  Ann Hematol       Date:  2013-10-27       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.